Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Gastroenterology
Erschienen in:

17.06.2022 | Irritable Bowel Diseases (D Adams, Section Editor)

Sarcopenia in Inflammatory Bowel Diseases: Reviewing Past Work to Pave the Path for the Future

verfasst von: Adam S. Faye, MD, MS, Tasnin Khan, BS, MS, Sandhya Cautha, MD, Bharati Kochar, MD, MS

Erschienen in: Current Treatment Options in Gastroenterology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of the Review

Sarcopenia is the loss of muscle quantity and strength. It is highly prevalent in patients with inflammatory bowel disease (IBD) and is associated with periods of ongoing inflammation. This review will summarize the prior work in the field and highlight areas for future research.

Recent Findings

The presence of sarcopenia has been associated with adverse outcomes in different populations. Most recently, sarcopenia has been associated with adverse postoperative outcomes and an increased likelihood of surgery in IBD. Despite this, significant heterogeneity among these studies limits the ability to draw definitive conclusions.

Summary

The importance of sarcopenia in inflammatory bowel disease (IBD) is only beginning to be recognized. Future studies assessing its utility both as a risk stratification tool and a modifiable factor in IBD are needed.
Literatur
1.
2.
Marcell TJ. Review Article: Sarcopenia: causes, consequences, and preventions. J Gerontol A Biol Sci Med Sci. 2003;58:M911–6.PubMedCrossRef
3.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39:412–23.PubMedPubMedCentralCrossRef
4.
Kochar B, Jylhava J, Soderling J, et al. Prevalence and Implications of frailty in older adults with incident inflammatory bowel diseases: a nationwide cohort study. Clin Gastroenterol Hepatol 2022. [epub ahead of print].
5.
Faye AS, Wen T, Soroush A, et al. Increasing prevalence of frailty and its association with readmission and mortality among hospitalized patients with IBD. Dig Dis Sci 2021;66(12):4178–90.
6.
Faye AS, Colombel J-F. Aging and IBD: a new challenge for clinicians and researchers. Inflamm Bowel Dis 2022;28(1):126–32.
7.
Kochar B, Orkaby AR, Ananthakrishnan AN, et al. Frailty in inflammatory bowel diseases: an emerging concept. Ther Adv Gastroenterol. 2021;14:175628482110254.CrossRef
8.
9.
10.
11.
Balage M, Averous J, Remond D, et al. Presence of low-grade inflammation impaired postprandial stimulation of muscle protein synthesis in old rats. J Nutr Biochem. 2010;21:325–31.PubMedCrossRef
12.
Schakman O, Dehoux M, Bouchuari S, et al. Role of IGF-I and the TNFalpha/NF-kappaB pathway in the induction of muscle atrogenes by acute inflammation. Am J Physiol Endocrinol Metab. 2012;303:E729–39.PubMedPubMedCentralCrossRef
13.
Sakuma K, Aoi W, Yamaguchi A. Current understanding of sarcopenia: possible candidates modulating muscle mass. Pflugers Arch. 2015;467:213–29.PubMedCrossRef
14.
Bian A-L, Hu H-Y, Rong Y-D, et al. A study on relationship between elderly sarcopenia and inflammatory factors IL-6 and TNF-α. Eur J Med Res 2017;22(1):25.
15.
Beyer I, Bautmans I, Njemini R, et al. Effects on muscle performance of NSAID treatment with piroxicam versus placebo in geriatric patients with acute infection-induced inflammation. A double blind randomized controlled trial. BMC Musculoskel Disord. 2011;12:292.CrossRef
16.
17.
Unal NG, Oruc N, Tomey O, et al. Malnutrition and sarcopenia are prevalent among inflammatory bowel disease patients with clinical remission. Eur J Gastroenterol Hepatol 2021;33(11):1367–75.
18.
Atlan L, Cohen S, Shiran S, et al. Sarcopenia is a predictor for adverse clinical outcome in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2021;72:883–8.PubMedCrossRef
19.
Lee CH, Yoon H, Oh DJ, et al. The prevalence of sarcopenia and its effect on prognosis in patients with Crohn’s disease. Intest Res. 2020;18:79–84.PubMedPubMedCentralCrossRef
20.
Cushing KC, Kordbacheh H, Gee MS, et al. Sarcopenia is a novel predictor of the need for rescue therapy in hospitalized ulcerative colitis patients. J Crohns Colitis 2018;12(9):1036–41.
21.
Dhaliwal A, Williams FR, Quinlan JI, et al. Evaluation of the mechanisms of sarcopenia in chronic inflammatory disease: protocol for a prospective cohort study. Skelet Muscle 2021;11(1):27.
22.
Simonsen C, de Heer P, Bjerre ED, et al. Sarcopenia and postoperative complication risk in gastrointestinal surgical oncology: a meta-analysis. Ann Surg. 2018;268:58–69.PubMedCrossRef
23.
Pedersen M, Cromwell J, Nau P. Sarcopenia is a predictor of surgical morbidity in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:1867–72.PubMedCrossRef
24.
Carvalho D, Viana C, Marques I, et al. Sarcopenia is associated with postoperative outcome in patients with Crohn’s disease undergoing bowel resection. Gastrointest Disord. 2019;1:201–9.CrossRef
25.
Fujikawa H, Araki T, Okita Y, et al. Impact of sarcopenia on surgical site infection after restorative proctocolectomy for ulcerative colitis. Surg Today. 2017;47:92–8.PubMedCrossRef
26.
Zhang T, Cao L, Cao T, et al. Prevalence of sarcopenia and its impact on postoperative outcome in patients With Crohn’s disease undergoing bowel resection. J Parenter Enter Nutr. 2017;41:592–600.CrossRef
27.
O’Brien S, Kavanagh RG, Carey BW, et al. The impact of sarcopenia and myosteatosis on postoperative outcomes in patients with inflammatory bowel disease. Euro Radiol Exp 2018;2.
28.
Alipour O, Lee V, Tejura TK, et al. The assessment of sarcopenia using psoas muscle thickness per height is not predictive of post-operative complications in IBD. Scand J Gastroenterol. 2021;56:1175–81.PubMedCrossRef
29.
Ryan E, McNicholas D, Creavin B, et al. Sarcopenia and inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2019;25:67–73.PubMedCrossRef
30.
Erős A, Soós A, Hegyi P, et al. Sarcopenia as an independent predictor of the surgical outcomes of patients with inflammatory bowel disease: a meta-analysis. Surg Today. 2020;50:1138–50.PubMedCrossRef
31.
Bamba S, Sasaki M, Takaoka A, et al. Sarcopenia is a predictive factor for intestinal resection in admitted patients with Crohn’s disease. PLoS ONE. 2017;12:e0180036.PubMedPubMedCentralCrossRef
32.
Ge X, Xia J, Wu Y, et al. Sarcopenia assessed by computed tomography is associated with colectomy in patients with acute severe ulcerative colitis. Eur J Clin Nutr 2021.
33.
Stenholm S, Harris TB, Rantanen T, et al. Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care. 2008;11:693–700.PubMedPubMedCentralCrossRef
34.
35.
36.
Adams DW, Gurwara S, Silver HJ, et al. Sarcopenia is common in overweight patients with inflammatory bowel disease and may predict need for surgery. Inflamm Bowel Dis. 2017;23:1182–6.PubMedCrossRef
37.
38.
Beckwee D, Delaere A, Aelbrecht S, et al. Exercise interventions for the prevention and treatment of sarcopenia. A systematic umbrella review. J Nutr Health Aging. 2019;23:494–502.PubMedCrossRef
39.
Beaudart C, Dawson A, Shaw SC, et al. Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporos Int. 2017;28:1817–33.PubMedPubMedCentralCrossRef
40.
Cruz-Jentoft AJ, Landi F, Schneider SM, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing. 2014;43:748–59.PubMedPubMedCentralCrossRef
41.
Cruz-Jentoft AJ, Romero-Yuste S, Chamizo Carmona E, et al. Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions. Aging Clin Exp Res 2021;33(11):2929–39.
42.
43.
Zhang T, Ding C, Xie T, et al. Skeletal muscle depletion correlates with disease activity in ulcerative colitis and is reversed after colectomy. Clin Nutr. 2017;36:1586–92.PubMedCrossRef
44.
Subramaniam K, Fallon K, Ruut T, et al. Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn’s disease. Aliment Pharmacol Ther. 2015;41:419–28.PubMedCrossRef
45.
Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31. PubMedCrossRef
46.
Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol Ser A. 2014;69:547–58.CrossRef
47.
Bamba S, Inatomi O, Takahashi K, et al. Assessment of body composition from CT Images at the level of the third lumbar vertebra in inflammatory bowel disease. Inflamm Bowel Dis. 2021;27:1435–42.PubMedCrossRef
48.
Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18:56–66.PubMedCrossRef
49.
Prado CMM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15:2920–6.PubMedCrossRef
50.
Ganju RG, Morse R, Hoover A, et al. The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiation. Radiother Oncol. 2019;137:117–24.PubMedCrossRef
Metadaten
Titel
Sarcopenia in Inflammatory Bowel Diseases: Reviewing Past Work to Pave the Path for the Future
verfasst von
Adam S. Faye, MD, MS
Tasnin Khan, BS, MS
Sandhya Cautha, MD
Bharati Kochar, MD, MS
Publikationsdatum
17.06.2022
Verlag
Springer US
Erschienen in
Current Treatment Options in Gastroenterology / Ausgabe 3/2022
Print ISSN: 1092-8472
Elektronische ISSN: 1534-309X
DOI
https://doi.org/10.1007/s11938-022-00389-8

Weitere Artikel der Ausgabe 3/2022

Genetic Testing in Acute and Chronic Pancreatitis

  • Open Access
  • Pancreas (C Forsmark, Section Editor)

The Role of Statins in Cirrhosis

  • Liver (E Tapper, Section Editor)

Primary Biliary Cholangitis

  • Pancreas(C Forsmark, Section Editor)

Eosinophilic Gastritis and Eosinophilic Duodenitis

  • Open Access
  • Stomach (P Malfertheiner, Section Editor)

Behavioral Interventions After Bariatric Surgery

  • Nutrition and Obesity (O Pickett-Blakely, Section Editor)

Evidence-Based Endoscopic Management of Benign Biliary Strictures

  • Pancreas (C Forsmark, Section Editor)

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Verbände und Cremes gegen Dekubitus: „Wir wissen nicht, was sie bringen!“

Die Datenlage zur Wirksamkeit von Verbänden oder topischen Mitteln zur Prävention von Druckgeschwüren sei schlecht, so die Verfasser einer aktuellen Cochrane-Studie. Letztlich bleibe es unsicher, ob solche Maßnahmen den Betroffenen nutzen oder schaden.

Schützt das tägliche Glas Milch vor Darmkrebs?

Die Milch machts – sie bietet Frauen nach Daten einer großen Ernährungsanalyse den besten Darmkrebsschutz aller Lebensmittel, was am hohen Kalziumgehalt liegen dürfte. Am anderen Ende des Spektrums steht der Alkoholkonsum: Das Glas Wein am Abend ist eher ungünstig.

Vorsicht mit Glukokortikoiden bei Glomerulopathie

Auch niedrig dosierte Glukokortikoide zur Behandlung einer primären Glomerulopathie lassen offenbar die Infektionsgefahr steigen. In einer US-Studie hing das Risiko vor allem mit der kombinierten Anwendung von Immunsuppressiva zusammen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise